These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 18257813

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T, Lanthanum Carbonate Research Group.
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [Abstract] [Full Text] [Related]

  • 4. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
    Joy MS, Finn WF, LAM-302 Study Group.
    Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
    Lee YK, Choi HY, Shin SK, Lee HY.
    Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
    [Abstract] [Full Text] [Related]

  • 8. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
    Hutchison AJ, Laville M, SPD405-313 Lanthanum Study Group.
    Nephrol Dial Transplant; 2008 Nov; 23(11):3677-84. PubMed ID: 18577536
    [Abstract] [Full Text] [Related]

  • 9. Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients.
    Hutchison AJ, Gill M, Copley JB, Poole L, Wilson RJ.
    BMC Nephrol; 2013 Feb 18; 14():40. PubMed ID: 23418668
    [Abstract] [Full Text] [Related]

  • 10. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
    Chiang SS, Chen JB, Yang WC.
    Clin Nephrol; 2005 Jun 18; 63(6):461-70. PubMed ID: 15960148
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
    Kishi Y, Obara Y, Hara K, Yamashiro H, Kurosawa N, Takada D.
    Ther Apher Dial; 2014 Jun 18; 18 Suppl 1():9-13. PubMed ID: 24953760
    [Abstract] [Full Text] [Related]

  • 17. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
    Zhao L, Liu A, Xu G.
    Ren Fail; 2021 Dec 18; 43(1):1378-1393. PubMed ID: 34602015
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
    Rombolà G, Londrino F, Corbani V, Falqui V, Ardini M, Zattera T, Liguria and Toscana Lanthanum Experience (LITOLAE) Group.
    J Nephrol; 2012 Dec 18; 25(4):490-6. PubMed ID: 22476966
    [Abstract] [Full Text] [Related]

  • 20. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA, Galani VJ, Shah PR.
    Saudi J Kidney Dis Transpl; 2014 May 18; 25(3):530-8. PubMed ID: 24821148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.